Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Study ID
NCT01910610
Phase
PHASE3
Status
Unknown

Conditions

  • Colorectal Cancer Metastatic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

STRATEGIC-1 is a study designed to determine the best sequence of therapy in patients with metastatic colorectal cancer.

Key Dates

Start date
Oct 30, 2013
Status verified
Mar 2024
Primary completion
Jul 13, 2023
Completion
Dec 31, 2024

Study Design

Enrollment
464 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: STRATEGY A
    FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
  • Experimental: STRATEGY B
    OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan

Primary Outcome Measure

Duration of Disease Control (DDC) [ Time Frame: From baseline until end of strategy; up to 80 months after the beginning of the study ]

Related Studies